entertainment -WSS

entertainment

author：fashion 2025-10-01 05:38:25 - browse：9237

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Evacuations in place as 3 wildfires burn in eastern Washington state

WSS

Trump's false claims about Georgia's 2020 election long debunked

New details revealed about Purdue's marketing of OxyContin

In early work, researchers turn to CRISPR to treat Alzheimer's

AI can’t replace a physician’s gut feeling

Listen: Wegovy in the brain & pivotal Alzheimer's data

Cancer drug shortages' outsize impact on ovarian cancer patients

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

As digital health tech proliferates, a new institute aims to cut through hype

23andMe had bad news about my health. I wish a person had delivered it

As Maui death toll rises, number of missing remains unclear

The high cost of giving birth even with insurance

Custom gene therapy hints at new path for rare disease treatments

23andMe had bad news about my health. I wish a person had delivered it

The pain doctors face in trying to build their families

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A public scorecard can help hold safety

hotspot

Ukraine taking heavy casualties 10 weeks into its counteroffensive

FDA approves RSV monoclonal antibody for infants, toddlers

In early work, researchers turn to CRISPR to treat Alzheimer's

How dance can help nurses traumatized by Covid

Listen: Wegovy in the brain & pivotal Alzheimer's data

In early work, researchers turn to CRISPR to treat Alzheimer's

focus

focus

hotspot

Wikipedia